![Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials - The Lancet Respiratory Medicine Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/attachment/c25ce520-d08e-4384-87a8-f9c2a4b3e13c/gr1a.gif)
Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials - The Lancet Respiratory Medicine
![Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study - The Lancet Healthy Longevity Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study - The Lancet Healthy Longevity](https://www.thelancet.com/cms/attachment/53df1219-ef81-4be7-9e58-949baca55d1a/gr1_lrg.jpg)
Antibody and cellular immune responses following dual COVID-19 vaccination within infection-naive residents of long-term care facilities: an observational cohort study - The Lancet Healthy Longevity
![3: Improving research on race, ethnicity and health inequalities in: Engaging Black and Minority Ethnic Groups in Health Research 3: Improving research on race, ethnicity and health inequalities in: Engaging Black and Minority Ethnic Groups in Health Research](https://bristoluniversitypressdigital.com/cover/covers/9781447359159.jpg)
3: Improving research on race, ethnicity and health inequalities in: Engaging Black and Minority Ethnic Groups in Health Research
![Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges - The Lancet Infectious Diseases Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges - The Lancet Infectious Diseases](https://www.thelancet.com/cms/attachment/072d5215-6138-481a-b850-c31066e41684/gr1_lrg.jpg)
Evaluating improved inactivated oral cholera vaccines for use in ending endemic cholera by 2030: opportunities and challenges - The Lancet Infectious Diseases
![Risk factors for multisystem inflammatory syndrome in children – A population-based cohort study of over 2 million children - The Lancet Regional Health – Europe Risk factors for multisystem inflammatory syndrome in children – A population-based cohort study of over 2 million children - The Lancet Regional Health – Europe](https://www.thelancet.com/cms/attachment/ea43f8b1-4d53-4ff9-82a3-52539da06281/gr1_lrg.jpg)
Risk factors for multisystem inflammatory syndrome in children – A population-based cohort study of over 2 million children - The Lancet Regional Health – Europe
![IJERPH | Free Full-Text | Family Function and Child Adjustment Difficulties in the COVID-19 Pandemic: An International Study IJERPH | Free Full-Text | Family Function and Child Adjustment Difficulties in the COVID-19 Pandemic: An International Study](https://www.mdpi.com/ijerph/ijerph-18-11136/article_deploy/html/images/ijerph-18-11136-g001.png)